Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced Breast Cancer 1

Interventions

Fulvestrant 5Letrozole 4Capecitabine 3pyrotinib 2Paclitaxel 2Goserelin 2Anastrozole 2palbociclib 1olaparib 1neratinib 1liposomal doxorubicin 1exemestane 1entinostat 1ceralasertib 1capivasertib 1Vinorelbine 1Trastuzumab 1Standard of Care 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Injections 1In Situ Hybridization, Fluorescence 1Immunotherapy, Adoptive 1Gonadotropin-Releasing Hormone 1FCN-437c 1Docetaxel 1Decitabine 1Cyclophosphamide 1Combined Modality Therapy 1Cisplatin 1CYH33 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Breast Cancer × entinostat × Clear all
NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡